Open-label study of donepezil in traumatic brain injury.
Arch Phys Med Rehabil
; 82(7): 896-901, 2001 Jul.
Article
in En
| MEDLINE
| ID: mdl-11441374
ABSTRACT
OBJECTIVE:
To determine preliminarily whether donepezil will improve memory, behavior, and global function after chronic traumatic brain injury (TBI).DESIGN:
Sixteen-week open-label study.SETTING:
Outpatient TBI rehabilitation program. PATIENTS Four patients with chronic, severe TBI.INTERVENTIONS:
Donepezil 5mg daily for 8 weeks followed by 10mg daily for 4 weeks. MAIN OUTCOMEMEASURES:
Memory measures included the Rey Auditory Verbal Learning Test (RAVLT), the Complex Figure Test (CFT), items from the Rivermead Behavioural Memory Test (RBMT), and a semantic fluency task. The Neuropsychiatric Inventory (NPI) evaluated behavior and affect. Function was assessed by using the FIM instrument and a clinical global impression of change.RESULTS:
On the RAVLT, the mean scores for learning and short- and long-term recall improved by 0.4, 1.04, and.83 standard deviations (SDs) above baseline, respectively. On the CFT, the mean scores for short-term recall and long-term recall improved by 1.56 and 1.38 SDs above baseline, respectively. A positive trend was observed on the RBMT and on the NPI subscales.CONCLUSIONS:
Donepezil may improve some aspects of memory and behavior in persons with chronic TBI. Randomized clinical trials are required to support these preliminary findings.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Piperidines
/
Brain Injuries
/
Nootropic Agents
/
Indans
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Arch Phys Med Rehabil
Year:
2001
Document type:
Article
Affiliation country:
Canadá